This program has already taken place.The ASCO Pre-Annual Meeting Seminar was created by the American Society of Clinical Oncology (ASCO), co-sponsored with the Society for Immunotherapy of Cancer (SITC). This seminar enabled clinical oncologists, nurses, pharmacists, and the entire medical team to effectively offer their patients additional treatment options through immunotherapy. Advances in cancer immunotherapy research are rapidly emerging, with an increasing rate of new approvals for the routine clinical use of immunotherapy agents in the clinic across a variety of cancers. The pace of progress in the field necessitates the continuing education of oncology clinicians to enable them to provide the most up-to-date and comprehensive immunotherapy-based treatment options to their patients. In addition, oncologists, nurses and pharmacists with basic knowledge related to utilizing immunotherapy in clinical practice continue to be challenged by issues related to patient selection and toxicity management.
Day 1: Thursday, May 31, 2018: 12:30 PM - 5:00 PM
12:30 p.m. – 1:00 p.m.
1:00 p.m. – 1:25 p.m.
Session 1: Basic Principles of Immunotherapy
Immunotherapy Basics Mario Sznol, MD - Yale School of Medicine
Panel Question and Answer
1:25 p.m. – 2:55 p.m.
Session 2: Integrating Immunotherapy Into Clinical Practice—Changes Over the Past Year (Part 1)
Melanoma and Other Skin Cancers Michael A. Postow, MD - Memorial Sloan Kettering Cancer Center Question and Answer
Lung Cancer Naiyer A. Rizvi, MD - Columbia University Medical Center Question and Answer
Breast and Gynecologic Cancers Leisha A. Emens, MD, PhD - The Johns Hopkins University Question and Answer
2:55 p.m. - 3:10 p.m.
3:10 p.m. - 5:00 p.m.
Session 2: Integrating Immunotherapy Into Clinical Practice—Changes Over the Past Year (Part 2)
Gastrointestinal Cancers Michael Morse, MD - Duke University School of Medicine Question and Answer
Genitourinary Cancers Neeraj Agarwal, MD - Huntsman Cancer Institute at the University of Utah Question and Answer
Head and Neck Cancers Robert L. Ferris, MD, PhD, FACS - University of Pittsburgh Medical Center and University of Pittsburgh Cancer Institute Question and Answer
The Impact of Immunotherapy On A Community Practice Alexander I. Spira, MD, PhD, FACP - Virginia Cancer Specialists Research Institute and Oncology Research Question and Answer
Day 2: Friday, June 1, 2018: 7:00 AM - 11:00 AM
7:00 a.m. – 7:30 a.m.
7:30 a.m. – 8:15 a.m.
Session 3: Hematologic Malignancies and CAR-T Cell Therapy
Mario Sznol, MD - Yale School of MedicineHematologic Malignancies John Timmerman, MD – University of California, Los Angeles
Clinical Application of Cell Therapies: Mechanism of Action, Efficacy, and Patient Selection Kevin J. Curran, MD - Memorial Sloan Kettering Cancer Center
8:15 a.m. – 8:30 a.m.
8:30 a.m. – 10:30 a.m.
Session 4: Managing Immune-Related Adverse Events—The Challenge to Maximize the Risk/Benefit Ratio
A Case-based Panel Discussion Mario Sznol, MD - Yale School of MedicineRavi A. Madan, MD – National Cancer InstituteKrista Rubin, APRN-BC - Massachusetts General HospitalNurse PerspectiveJoachim M. Baehring, MD - Yale School of MedicineNeurologist PerspectiveJaydira Del Rivero, MD - National Cancer InstituteEndocrinologist PerspectiveElizabeth J. Shpall, MD - The University of Texas MD Anderson Cancer CenterCell Therapist/Benign Hematologist Perspective
10:30 a.m. – 11:00 a.m.
Session 5: The Future of Immunotherapy—Novel Agents in Clinical Trials
Ravi A. Madan, MD – National Cancer InstituteNew Agents in Clinical Trials: Significant Phase I-III Clinical TrialJames Gulley, MD, PhD - National Cancer Institute
Tel: +1 414 271 2456 | Fax: +1 414 276 3349 | Email: email@example.com